Ipilimumab/nivolumabGrade 3 autoimmune hepatitis: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1929卷 / 1期

关键词：

D O I：

10.1007/s40278-022-25983-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：359 / 359

相关论文

共 50 条

[1] Ipilimumab/nivolumabGrade 3 colitis: case report
Reactions Weekly, 2023, 1986 (1) : 222 - 222
[2] Ipilimumab/nivolumab/NivolumabGrade 3 haemorrhagic gastritis and grade 3 hepatitis: case report
Reactions Weekly, 2025, 2040 (1) : 497 - 497
[3] Ipilimumab/nivolumabGrade-3 enterocolitis : case report
Reactions Weekly, 2024, 2018 (1) : 253 - 253
[4] Ipilimumab/nivolumabGrade 3 transaminitis and acute cholecystitis: case report
Reactions Weekly, 2025, 2056 (1) : 260 - 260
[5] Ipilimumab/nivolumabAutoimmune hepatitis and autoimmune thyroiditis: case report
Reactions Weekly, 2017, 1665 (1) : 162 - 162
[6] Ipilimumab/nivolumabThrombocytopenia, neutropenia and autoimmune hepatitis: case report
Reactions Weekly, 2018, 1725 (1) : 184 - 184
[7] NivolumabGrade 3 immune-related hepatitis: case report
Reactions Weekly, 2018, 1709 (1) : 185 - 185
[8] Ipilimumab/pembrolizumabDiarrhoea, autoimmune hepatitis and eosinophilic fasciitis: case report
Reactions Weekly, 2019, 1778 (1) : 260 - 260
[9] NivolumabGrade 3 diarrhoea: case report
Reactions Weekly, 2017, 1658 (1) : 350 - 350
[10] Ipilimumab/nivolumabEpidermolysis bullosa aquisita, autoimmune hepatitis and sinusitis: case report
Reactions Weekly, 2022, 1916 (1) : 239 - 239

← 1 2 3 4 5 →